Published in Infect Immun on December 10, 2012
Neisseria adhesin A variation and revised nomenclature scheme. Clin Vaccine Immunol (2014) 0.99
Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol (2014) 0.93
Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. Proc Natl Acad Sci U S A (2014) 0.92
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. J Immunol Res (2015) 0.85
Temporal Changes in BEXSERO® Antigen Sequence Type Associated with Genetic Lineages of Neisseria meningitidis over a 15-Year Period in Western Australia. PLoS One (2016) 0.82
Molecular Basis of Ligand-Dependent Regulation of NadR, the Transcriptional Repressor of Meningococcal Virulence Factor NadA. PLoS Pathog (2016) 0.80
Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine Against Genetically Diverse Serogroup B Meningococci. Clin Vaccine Immunol (2016) 0.79
Predicted Strain Coverage of a New Meningococcal Multicomponent Vaccine (4CMenB) in Spain: Analysis of the Differences with Other European Countries. PLoS One (2016) 0.77
Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes. J Immunol Res (2015) 0.76
Meningococcal B vaccine and the vision of a meningitis free world. J Prev Med Hyg (2015) 0.76
Licensed meningococcal serogroup B vaccine-induced immunity against invasive disease does not reflect protection against nasal colonization in a humanized mouse model. J Infect Dis (2017) 0.75
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem (2009) 23.19
Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 13.87
Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med (1969) 9.01
Meningococcal disease. N Engl J Med (2001) 8.50
Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med (1969) 6.17
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet (2007) 5.11
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med (1969) 3.96
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis (2007) 2.70
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis (2010) 2.24
Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun (1987) 2.09
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun (1999) 1.76
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J (2010) 1.73
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol (2005) 1.51
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol (2001) 1.28
Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis (2004) 1.27
A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog (2009) 1.17
The iron-responsive regulator fur is transcriptionally autoregulated and not essential in Neisseria meningitidis. J Bacteriol (2003) 1.09
OxyR tightly regulates catalase expression in Neisseria meningitidis through both repression and activation mechanisms. Mol Microbiol (2008) 1.03
Human monocytes/macrophages are a target of Neisseria meningitidis Adhesin A (NadA). J Leukoc Biol (2008) 0.96
Mechanism for attenuation of DNA binding by MarR family transcriptional regulators by small molecule ligands. J Mol Biol (2009) 0.91
The presence of 4-hydroxyphenylacetic acid in human saliva and the possibility of its nitration by salivary nitrite in the stomach. FEBS Lett (2002) 0.91
The soluble recombinant Neisseria meningitidis adhesin NadA(Δ351-405) stimulates human monocytes by binding to extracellular Hsp90. PLoS One (2011) 0.90
In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva. J Bacteriol (2011) 0.90
IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol (2007) 0.90
The metabolism and dechlorination of chlorotyrosine in vivo. J Biol Chem (2007) 0.88
Peroxynitrite formation from activated human leukocytes. Biochem Biophys Res Commun (1996) 0.87
Meningococcal pathogenesis: at the boundary between the pre- and post-genomic eras. Curr Opin Microbiol (2001) 0.86
Structural insight into the mechanism of DNA-binding attenuation of the Neisserial adhesin repressor NadR by the small natural ligand 4-hydroxyphenylacetic acid. Biochemistry (2012) 0.85
Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine (2009) 0.84
Real-space imaging of alternate localization and extension of quasi-two-dimensional electronic States at graphite surfaces in magnetic fields. Phys Rev Lett (2006) 0.81
Characterization of encapsulated and noncapsulated Haemophilus influenzae and determination of phylogenetic relationships by multilocus sequence typing. J Clin Microbiol (2003) 4.47
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis (2008) 3.98
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci U S A (2005) 3.59
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol (2006) 3.03
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect (2002) 2.37
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
How did Sierra Leone provide free health care? Lancet (2011) 2.12
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol (2007) 2.01
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis (2011) 1.99
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review. Vaccine (2010) 1.91
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol (2008) 1.71
Evolution of competence and DNA uptake specificity in the Pasteurellaceae. BMC Evol Biol (2006) 1.71
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Expression profiling the temperature-dependent amphibian response to infection by Batrachochytrium dendrobatidis. PLoS One (2009) 1.64
Improved detection of bifidobacteria with optimised 16S rRNA-gene based pyrosequencing. PLoS One (2012) 1.62
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
A novel CRP-dependent regulon controls expression of competence genes in Haemophilus influenzae. J Mol Biol (2005) 1.57
Acid-induced activation of the urease promoters is mediated directly by the ArsRS two-component system of Helicobacter pylori. Infect Immun (2005) 1.56
Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine (2013) 1.49
Skeletal lead release during bone resorption: effect of bisphosphonate treatment in a pilot study. Environ Health Perspect (2002) 1.44
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine (2009) 1.44
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog (2011) 1.42
NadA diversity and carriage in Neisseria meningitidis. Infect Immun (2004) 1.40
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics (2006) 1.39
Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol (2010) 1.36
Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol (2009) 1.32
Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine (2010) 1.30
Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. Mol Microbiol (2006) 1.30
Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteomics (2007) 1.30
Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure. Proc Natl Acad Sci U S A (2014) 1.27
Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis (2004) 1.27
The RNA chaperone Hfq is involved in stress response and virulence in Neisseria meningitidis and is a pleiotropic regulator of protein expression. Infect Immun (2009) 1.27
Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun (2010) 1.24
In vivo dissection of the Helicobacter pylori Fur regulatory circuit by genome-wide location analysis. J Bacteriol (2006) 1.24
Characterization of a novel Neisseria meningitidis Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Mol Microbiol (2004) 1.24
Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis. J Biol Chem (2005) 1.23
Ng-MIP, a surface-exposed lipoprotein of Neisseria gonorrhoeae, has a peptidyl-prolyl cis/trans isomerase (PPIase) activity and is involved in persistence in macrophages. Mol Microbiol (2005) 1.22
Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis (2011) 1.19
Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine (2005) 1.19
Identification of Actinobacillus pleuropneumoniae genes important for survival during infection in its natural host. Infect Immun (2003) 1.18
Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J Mol Biol (2008) 1.17
A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog (2009) 1.17
U.K. parents' decision-making about measles-mumps-rubella (MMR) vaccine 10 years after the MMR-autism controversy: a qualitative analysis. Vaccine (2012) 1.17
Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. PLoS One (2009) 1.17
Phosphate flow in the chemotactic response system of Helicobacter pylori. Microbiology (2005) 1.17
Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proc Natl Acad Sci U S A (2013) 1.16